Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States.

CONCLUSIONS: Esketamine is unlikely to be cost-effective for management of treatment-resistant depression in the United States unless its price falls by more than 40%. PMID: 32631129 [PubMed - as supplied by publisher]
Source: Psychiatric Services - Category: Psychiatry Tags: Psychiatr Serv Source Type: research